OrbiMed Advisors TERN Position
Active10-Fund ConvergenceOrbiMed Advisors trimmed their position in Terns Pharmaceuticals Inc. (TERN) in Q4 2025, holding $87.0M worth of shares across 2,153,300 shares.
The position was first reported in Q1 2023 and has been tracked across 12 quarterly 13F filings.
TERN is a convergence signal: 10 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for TERN-701 in 1324 days (Nov 30, 2029), making the timing of OrbiMed's position particularly relevant.
Short interest stands at 16.2% of float with 9.1 days to cover, indicating significant bearish positioning against OrbiMed's long thesis.
About Terns Pharmaceuticals Inc.
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Full company profile →Short Interest
16.2%
9.1 days to cover
OrbiMed Advisors TERN Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 2,153,300 | -5,409,671 | $87.0M |
| Q3 2025 | Held | 7,562,971 | — | $56.8M |
| Q2 2025 | Held | 7,562,971 | — | $28.2M |
| Q1 2025 | Held | 7,562,971 | — | $20.9M |
| Q4 2024 | Held | 7,562,971 | — | $41.9M |
| Q3 2024 | Decreased | 7,562,971 | -56,164 | $63.1M |
| Q2 2024 | Held | 7,619,135 | — | $51.9M |
| Q1 2024 | Held | 7,619,135 | — | $50.0M |
| Q4 2023 | Held | 7,619,135 | — | $49.4M |
| Q3 2023 | Held | 7,619,135 | — | $38.3M |
| Q2 2023 | Held | 7,619,135 | — | $66.7M |
| Q1 2023 | New | 7,619,135 | +7,619,135 | $90.2M |
Frequently Asked Questions
Does OrbiMed Advisors own TERN?
Yes. As of Q4 2025, OrbiMed Advisors holds 2,153,300 shares of Terns Pharmaceuticals Inc. (TERN) valued at $87.0M. This data comes from their SEC 13F filing.
How many hedge funds own TERN?
10 specialist biotech hedge funds currently hold TERN, including Avoro Capital Advisors, Commodore Capital, Deep Track Capital and 6 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy TERN?
OrbiMed Advisors's position in TERN was first reported in Q1 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's TERN position increasing or decreasing?
OrbiMed Advisors trimmed their TERN position in the most recent quarter, reducing by 5,409,671 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
TERNCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →